As circulating inflammatory CC-chemokines will predominantly have derived from the original inflamed site, one intriguing possibility is that ACKR2 limits the activity of circulating chemokines and therefore potentially ameliorates the development of chemokine-associated comorbidities (e.g. atherosclerosis) in patients. The gene discussed is ACKR2; the disease is atherosclerosis.